Personalised type 2 diabetes therapy in primary care

The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in
low- and middle-income countries, where access to care and newer therapies is often limited(1).
Many people with type 2 diabetes also live with multiple long-term conditions (2), making their
management even more complex. The majority of these patients are treated in primary and
community care settings(3, 4), where clinicians face significant challenges in choosing appropriate
therapies amidst a growing number of medication classes. In this context, the study by Dennis et al.
offers a timely innovation by introducing a predictive model aimed at optimising glucose-lowering
therapy(5). [Opening paragraph]